Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient.
Post-transplant lymphoproliferative disorder (PTLD) is a complication of allogeneic bone marrow transplantation (BMT). Rare cases of PTLD after autologous BMT have been reported only in adults. This case report is the first to describe PTLD in a pediatric patient after autologous peripheral stem cell transplantation (PSCT). This 2-year-old male with stage IV neuroblastoma underwent autologous PSCT. The post-PSCT course was complicated by fever with hematochezia and a lung mass. On day 94 post PSCT, colonoscopy revealed an ulcer due to a PTLD, monomorphic type, B cell phenotype, associated with Epstein-Barr virus. Fine needle aspiration identified the lung mass as neuroblastoma. PTLD can occur in pediatric autologous PSCT recipients, and may occur more frequently in autologous grafts manipulated by T cell depletion or CD34+ cell selection.
Lones
M A
MA
Pathology Department, Children's Hospital of Orange County/St Joseph Hospital, Orange, CA 92863-5600, USA.
Kirov
I
I
Said
J W
JW
Shintaku
I P
IP
Neudorf
S
S
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000315:Adrenalectomy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003108:Colonic Diseases / Q000209:etiology / Q000821:virology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003586:Cytomegalovirus Infections / Q000209:etiology; D004317:Doxorubicin / Q000008:administration & dosage; D004381:Duodenal Ulcer / Q000209:etiology / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000150:complications; D005047:Etoposide / Q000008:administration & dosage; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000209:etiology* / Q000473:pathology / Q000821:virology; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D009918:Orbital Neoplasms / Q000556:secondary; D017096:Prion Diseases; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous; D014456:Ulcer / Q000209:etiology / Q000821:virology; D014750:Vincristine / Q000008:administration & dosage
D007166:Immunosuppressive Agents; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin